cymbalta: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Lilly	CYMBALTA	duloxetine hydrochloride	CAPSULE, DELAYED REL PELLETS;ORAL	021427	NDA	Eli Lilly and Company	0002-3235-60	60 CAPSULE, DELAYED RELEASE in 1 BOTTLE (0002-3235-60)	2004-08-24
Lilly	CYMBALTA	duloxetine hydrochloride	CAPSULE, DELAYED REL PELLETS;ORAL	021427	NDA	Eli Lilly and Company	0002-3240-30	30 CAPSULE, DELAYED RELEASE in 1 BOTTLE (0002-3240-30)	2004-08-24
Lilly	CYMBALTA	duloxetine hydrochloride	CAPSULE, DELAYED REL PELLETS;ORAL	021427	NDA	Eli Lilly and Company	0002-3240-90	90 CAPSULE, DELAYED RELEASE in 1 BOTTLE (0002-3240-90)	2004-08-24
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: August 1, 2025

Introduction

CYMBALTA (duloxetine hydrochloride) is a widely prescribed antidepressant classified as a serotonin-norepinephrine reuptake inhibitor (SNRI). Approved by the U.S. Food and Drug Administration (FDA) in 2004, CYMBALTA is used to treat major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathy, fibromyalgia, and chronic musculoskeletal pain. Its global demand catalyzes the need for a reliable supply chain comprising multiple specialized suppliers involved in the manufacturing of active pharmaceutical ingredients (APIs), excipients, and finished dosage forms.

This article provides a comprehensive overview of the primary and secondary suppliers involved in the CYMBALTA supply chain, highlighting key manufacturers, market dynamics, and strategic considerations for pharmaceutical stakeholders.

Active Pharmaceutical Ingredient (API) Suppliers

1. Major API Manufacturers

The core component of CYMBALTA is duloxetine hydrochloride, whose synthesis demands advanced chemical processes and high-quality standards. Several global players dominate API production, leveraging proprietary manufacturing technologies to meet stringent regulatory quality requirements.

Sun Pharmaceutical Industries Ltd.
As one of the world's leading pharmaceutical manufacturers, Sun Pharma maintains robust API manufacturing capabilities, including duloxetine hydrochloride. The company operates multiple facilities in India and abroad, adhering to cGMP standards, and supplies global markets per regulatory approvals.
H. R. Johnson & Co., Ltd.
This India-based API producer supplies duloxetine hydrochloride to various pharma companies, leveraging cost-effective manufacturing and a global distribution network.
Mitsubishi Tanabe Pharma Corporation
Located in Japan, Mitsubishi Tanabe has specialized chemistries for SNRI APIs. Its strategic focus on high-purity APIs aligns with the demand for quality in CNS therapies.
R-Pharm
A Russian pharmaceutical company with expanding API manufacturing capabilities, including duloxetine, R-Pharm supplies both domestic and international clients.

2. Emerging and Contract API Suppliers

The API market for duloxetine is dynamic, with contract manufacturing organizations (CMOs) offering cost-effective production:

Dr. Reddy’s Laboratories
Has partnered with CMOs for API synthesis, ensuring supply resilience amid fluctuating demand.
Aenova Group
Provides contract manufacturing services for APIs, including SNRI compounds.
Cambrex Corporation
Specializes in small-molecule APIs with flexible manufacturing capabilities conducive to customized supply solutions.

Excipients and Formulation Components

Excipients are critical for ensuring drug stability and bioavailability. Key suppliers include:

Evonik Industries
Offers pharmaceutical-grade excipients such as binders and fillers used in CYMBALTA tablets.
Ashland Global Holdings
Provides disintegrants, lubricants, and coating agents compliant with pharmacopeial standards.
Dow Chemical Company
Supplies polymers and stabilizers crucial for drug formulation.

Finished Pharmaceutical Product (FPP) Manufacturers

Major pharmaceutical companies that produce CYMBALTA under license or corporate ownership include:

Eli Lilly and Company
Originally developed and marketed CYMBALTA globally, including major markets like the U.S., Europe, and Japan. Eli Lilly oversees manufacturing, quality control, and distribution.
Lannett Company, Inc.
Licensed to produce generic versions in certain markets, ensuring broad availability and pricing competition.
S.W.O Pharma / S. W. O. Pharmaceuticals Ltd.
Engaged in manufacturing generic duloxetine formulations for regional markets.
Other local generics manufacturers
In markets like India, China, and Southeast Asia, regional manufacturers produce generic versions under local regulatory approvals, expanding global access.

Supply Chain Considerations

Reliability and Regulatory Compliance

API suppliers must meet international standards including USP, EP, JP, and ICH guidelines. Manufacturers holding Good Manufacturing Practice (GMP) certification provide assurance of quality, purity, and batch-to-batch consistency—a priority for regulated markets.

Geographical Diversification

A diversified supply chain reduces risk exposure to geopolitical tensions, natural disasters, or regulatory changes. Companies sourcing API from India, Europe, and Asia-Pacific regions mitigate dependency on single-source suppliers.

Market Dynamics

Recent geopolitical factors, such as US-China trade tensions and pandemic-driven supply disruptions, have prompted pharmaceutical companies to diversify their supplier base. Moreover, rising API manufacturing costs in some regions have increased reliance on contract manufacturing and regional suppliers.

Intellectual Property and Licensing

The original patent for CYMBALTA expired in many major jurisdictions by 2014, facilitating generic production. Currently, patent protection limits are primarily affecting proprietary formulations rather than APIs. Licensing agreements between originators and generic manufacturers enable broader market access while maintaining supply confidentiality.

Strategic Implications for Stakeholders

Manufacturers should ensure supplier qualification and establish multiple sourcing agreements to enhance resilience.
Distributors benefit from partnerships with API producers that have robust regulatory approvals.
Pharmaceutical companies must monitor geopolitical shifts and regulatory changes affecting API sources.
Regulatory agencies demand continued compliance with cGMP standards for all suppliers involved in the supply chain.

Key Takeaways

Global API landscape: Dominated primarily by Indian, Japanese, and European manufacturers, with a growing presence of CMOs offering flexible production.
Supply chain resilience: Diversification among API and excipient suppliers reduces risk and stabilizes supply for CYMBALTA.
Regulatory standards: Suppliers must meet strict international quality standards and hold GMP certifications.
Market trends: Increasing generic competition, licensing arrangements, and regional manufacturing capabilities influence supply dynamics.
Strategic sourcing: Biopharmaceutical companies should employ robust qualification processes and alternative sourcing strategies to ensure uninterrupted availability.

FAQs

1. Who are the primary API suppliers for CYMBALTA?
Major API producers include Sun Pharmaceutical Industries, Mitsubishi Tanabe Pharma, and R-Pharm, alongside contract manufacturers such as Dr. Reddy’s Laboratories and Cambrex.

2. Are there regional differences in CYMBALTA suppliers?
Yes. Indian firms dominate generic API supply, while original branded CYMBALTA relies on manufacturing hubs in North America and Japan. Regional manufacturers also produce generic formulations in markets like India, China, and Europe.

3. What quality standards do CYMBALTA API suppliers typically adhere to?
Suppliers conform to cGMP, USP, and EP standards, with certifications from relevant regulatory authorities such as the FDA, EMA, and PMI.

4. How do geopolitical factors affect the supply of CYMBALTA?
Trade tensions and global disruptions can impact API sourcing, prompting pharmaceutical companies to diversify their supply base and establish regional manufacturing partnerships.

5. What future trends could influence the supply chain for CYMBALTA?
Advancements in chemical synthesis, increasing manufacturing of biosimilars, regulatory changes, and market expansion into emerging economies will shape supply chain strategies.

Sources

U.S. Food and Drug Administration (FDA). "Cymbalta (Duloxetine) Data and Approval Details."
Sun Pharmaceutical Industries Ltd. Annual Report.
Mitsubishi Tanabe Pharma Corporation. Product Portfolio and API information.
Eli Lilly & Co. Official Website. Product and Manufacturing Standards.
Industry reports on pharmaceutical supply chain diversification and API manufacturers.

Suppliers and packagers for cymbalta

cymbalta

Suppliers for the Pharmaceutical Drug CYMBALTA